Lipoprotein(a). Its importance as an additional atherosclerosis marker.

Detalhes bibliográficos
Autor(a) principal: Campos, E
Data de Publicação: 1997
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374
Resumo: Lipoprotein(a) is one of the best examples of heterogeneity of lipoproteins. It presents pre-beta electrophoretic mobility in agarose gel, similar to Very Low Density Lipoproteins, it is found in High Density Lipoproteins due to its hydrated density greater than 1,063 and resembles Low Density Lipoproteins in its size and lipid composition. However, Lp(a) is unique in that it contains an additional distinct antigen, the apo(a), attached to apoB100 by one disulphide bridge. The apo(a)-glycoprotein has recently been shown to have a striking amino acid sequence homology with plasminogen; Lp(a) seems to be a potential bridge between atherosclerosis and thrombosis fields and interest in Lp(a) has greatly increased since then. The new knowledge on the structure of Lp(a) being more and more rapidly acquired should facilitate our understanding of the mechanisms of its atherogenicity and its physiopathological role. Metabolic studies have made it clear that Lp(a) is not a product derived from other apoB-containing lipoproteins, but is secreted by the liver as a distinct mature lipoprotein. Concerning the immunological techniques available to assay Lp(a) they need to be standardized and it is still necessary to define what is meant by the pathological threshold for Lp(a), which will certainly depend on the choice of the standard antiserum and immunological method used.
id RCAP_b5f7524fe66d5b5cef5008ec821b572a
oai_identifier_str oai:ojs.www.actamedicaportuguesa.com:article/2374
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Lipoprotein(a). Its importance as an additional atherosclerosis marker.Lipoproteina (a). Sua importância como marcador adicional de aterosclerose.Lipoprotein(a) is one of the best examples of heterogeneity of lipoproteins. It presents pre-beta electrophoretic mobility in agarose gel, similar to Very Low Density Lipoproteins, it is found in High Density Lipoproteins due to its hydrated density greater than 1,063 and resembles Low Density Lipoproteins in its size and lipid composition. However, Lp(a) is unique in that it contains an additional distinct antigen, the apo(a), attached to apoB100 by one disulphide bridge. The apo(a)-glycoprotein has recently been shown to have a striking amino acid sequence homology with plasminogen; Lp(a) seems to be a potential bridge between atherosclerosis and thrombosis fields and interest in Lp(a) has greatly increased since then. The new knowledge on the structure of Lp(a) being more and more rapidly acquired should facilitate our understanding of the mechanisms of its atherogenicity and its physiopathological role. Metabolic studies have made it clear that Lp(a) is not a product derived from other apoB-containing lipoproteins, but is secreted by the liver as a distinct mature lipoprotein. Concerning the immunological techniques available to assay Lp(a) they need to be standardized and it is still necessary to define what is meant by the pathological threshold for Lp(a), which will certainly depend on the choice of the standard antiserum and immunological method used.Lipoprotein(a) is one of the best examples of heterogeneity of lipoproteins. It presents pre-beta electrophoretic mobility in agarose gel, similar to Very Low Density Lipoproteins, it is found in High Density Lipoproteins due to its hydrated density greater than 1,063 and resembles Low Density Lipoproteins in its size and lipid composition. However, Lp(a) is unique in that it contains an additional distinct antigen, the apo(a), attached to apoB100 by one disulphide bridge. The apo(a)-glycoprotein has recently been shown to have a striking amino acid sequence homology with plasminogen; Lp(a) seems to be a potential bridge between atherosclerosis and thrombosis fields and interest in Lp(a) has greatly increased since then. The new knowledge on the structure of Lp(a) being more and more rapidly acquired should facilitate our understanding of the mechanisms of its atherogenicity and its physiopathological role. Metabolic studies have made it clear that Lp(a) is not a product derived from other apoB-containing lipoproteins, but is secreted by the liver as a distinct mature lipoprotein. Concerning the immunological techniques available to assay Lp(a) they need to be standardized and it is still necessary to define what is meant by the pathological threshold for Lp(a), which will certainly depend on the choice of the standard antiserum and immunological method used.Ordem dos Médicos1997-01-30info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374oai:ojs.www.actamedicaportuguesa.com:article/2374Acta Médica Portuguesa; Vol. 10 No. 1 (1997): Janeiro; 87-93Acta Médica Portuguesa; Vol. 10 N.º 1 (1997): Janeiro; 87-931646-07580870-399Xreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374/1789Campos, Einfo:eu-repo/semantics/openAccess2022-12-20T11:00:24Zoai:ojs.www.actamedicaportuguesa.com:article/2374Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:17:42.291748Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Lipoprotein(a). Its importance as an additional atherosclerosis marker.
Lipoproteina (a). Sua importância como marcador adicional de aterosclerose.
title Lipoprotein(a). Its importance as an additional atherosclerosis marker.
spellingShingle Lipoprotein(a). Its importance as an additional atherosclerosis marker.
Campos, E
title_short Lipoprotein(a). Its importance as an additional atherosclerosis marker.
title_full Lipoprotein(a). Its importance as an additional atherosclerosis marker.
title_fullStr Lipoprotein(a). Its importance as an additional atherosclerosis marker.
title_full_unstemmed Lipoprotein(a). Its importance as an additional atherosclerosis marker.
title_sort Lipoprotein(a). Its importance as an additional atherosclerosis marker.
author Campos, E
author_facet Campos, E
author_role author
dc.contributor.author.fl_str_mv Campos, E
description Lipoprotein(a) is one of the best examples of heterogeneity of lipoproteins. It presents pre-beta electrophoretic mobility in agarose gel, similar to Very Low Density Lipoproteins, it is found in High Density Lipoproteins due to its hydrated density greater than 1,063 and resembles Low Density Lipoproteins in its size and lipid composition. However, Lp(a) is unique in that it contains an additional distinct antigen, the apo(a), attached to apoB100 by one disulphide bridge. The apo(a)-glycoprotein has recently been shown to have a striking amino acid sequence homology with plasminogen; Lp(a) seems to be a potential bridge between atherosclerosis and thrombosis fields and interest in Lp(a) has greatly increased since then. The new knowledge on the structure of Lp(a) being more and more rapidly acquired should facilitate our understanding of the mechanisms of its atherogenicity and its physiopathological role. Metabolic studies have made it clear that Lp(a) is not a product derived from other apoB-containing lipoproteins, but is secreted by the liver as a distinct mature lipoprotein. Concerning the immunological techniques available to assay Lp(a) they need to be standardized and it is still necessary to define what is meant by the pathological threshold for Lp(a), which will certainly depend on the choice of the standard antiserum and immunological method used.
publishDate 1997
dc.date.none.fl_str_mv 1997-01-30
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374
oai:ojs.www.actamedicaportuguesa.com:article/2374
url https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374
identifier_str_mv oai:ojs.www.actamedicaportuguesa.com:article/2374
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/2374/1789
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv Acta Médica Portuguesa; Vol. 10 No. 1 (1997): Janeiro; 87-93
Acta Médica Portuguesa; Vol. 10 N.º 1 (1997): Janeiro; 87-93
1646-0758
0870-399X
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130630053691392